March 24th, 2022 | 10:58 CET
Nel and Bayer shares in demand - when will Barsele Minerals explode?
The stock and commodity markets remain volatile. Prices are driven by the war in Ukraine and the Corona pandemic. In recent days, commodities have been on the rise again. Brent oil is trading at around USD 120 per barrel, and gold is again setting its sights on the USD 2,000 mark. But even in this difficult-to-navigate environment, equities can make gains. Bayer shares, for example, have developed positively in recent weeks. And analysts see up to 50% upside potential for the DAX company. The invasion of Russia has also accelerated the move toward renewable energies. Hydrogen plays a central role in this. Nel has been able to profit from the fantasy in recent weeks and has now also announced a new order. Gold explorer Barsele Minerals has catch-up potential. According to a study, the share already had a lot of potential at a gold price of USD 1,350.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
NEL ASA NK-_20 | NO0010081235 , BAYER AG NA O.N. | DE000BAY0017 , BARSELE MINERALS | CA0688921083
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Barsele Minerals a takeover candidate?
The Canadian exploration company Barsele Minerals is currently focusing on a project in Sweden. Compared to competition in Eastern Europe, Africa and Asia, this significantly reduces political risks. The Barsele Gold project is located 600km north of Stockholm. Several large gold deposits are located nearby, including Bjorkdal (Elgin Mining), Faboliden (Dragon Mining) and Svartliden (Dragon Mining). In recent years, 404 drill holes have been drilled at the Barsele project with a total length of 155,000m. The 2019 NI 43-101 compliant resource estimate indicated approximately 2.5 million ounces of gold. Currently, work is underway to expand this. The next milestone is to increase the resource estimate to 3.5 million ounces of gold.
Barsele has a strong partner at its side in the development of the project. Barsele holds 45% of the project. The senior partner with 55% is Agnico Eagle. The billion-dollar company is leading exploration on the property. An attempt by Barsele to take over the 55% failed a few months ago. But it remains exciting; perhaps Barsele itself becomes a takeover candidate because the valuation is low. The Royal Bank of Canada already valued the Barsele project at USD 375 million a few years ago. Barsele's market capitalization is around USD 50 million. The share is also traded on German stock exchanges. Important for the valuation: The basis for the valuation at that time was a gold price of USD 1,350. Today, the troy ounce is solidly quoted between USD 1,900 and 2,000. Barsele shares should therefore have room for improvement.
Bayer shares with up to 50% price potential
According to analysts, the Bayer share also has room for improvement. The stock of the DAX company has already performed well in recent weeks and is currently trading at just under EUR 60. UBS has a target price of EUR 90 and sees a potential of 50%. Accordingly, the analysts recommend Bayer's stock as a buy. Due to the glyphosate legal dispute, the stock has long been decoupled from the fundamental value. However, it is now time for this risk discount to be removed. The development in the agricultural division continues to be very dynamic. Important news is expected in April. Then it should become more clear how the Group is coping with the expiration of the patent for the anticoagulant Xarelto. Deutsche Bank also sees a share price potential of over 20%. Bayer has achieved an attractive price in the sale of the "Environmental Science Professional" business around professional pest control. Therefore, the analysts confirmed their buy recommendation with a target price of EUR 75.
Nel: Minister for Economic Affairs Habeck again creates share price fantasy
One can certainly not speak of a valuation discount for Nel. Instead, the share is driven by a lot of fantasy. Because when it comes to hydrogen, investors can hardly ignore the Norwegian Company. And hydrogen is becoming more than ever the central building block of the energy transition - especially in Germany. Economics Minister Habeck emphasized this once again during his visit to the Arabian Peninsula. Against the backdrop of the Russian attack on Ukraine, the development of a hydrogen economy could happen much faster than previously planned, Habeck said. According to his ideas, green hydrogen, produced without CO2 emissions based on renewable energies, should enable decarbonization in the steel and chemical industries, for example. Germany should then be able to do without fossil energies in the long term. Nel should benefit from the massive investment in hydrogen technology and has taken at least one small step with its latest order. The Company is to supply modules for a planned hydrogen station in Le Bourget, France. The customer is HysetCo, which operates hydrogen taxis in the Paris region. According to the Company, it operates the largest hydrogen taxi fleet globally. Nel manager Martin Pfandl said, "We are pleased to have been selected by HysetCo as a hydrogen refueling station equipment supplier. We look forward to supporting HysetCo in developing hydrogen mobility infrastructure in France."
Bayer and Nel are clearly in a short-term uptrend. That said, Nel is no bargain and has yet to grow into its billion-dollar valuation. The opposite is true for Barsele Minerals. The explorer is developing an exciting gold project with a strong partner and is anything but highly valued.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
